In a filing, Xeris Biopharma Holdings Inc revealed its Director Schmid John P. acquired Company’s shares for reported $9720.0 on Mar 14 ’24. In the deal valued at $2.16 per share,4,500 shares were bought. As a result of this transaction, Schmid John P. now holds 11,000 shares worth roughly $23210.0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, SHERMAN JEFFREY W bought 5,400 shares, generating $10,098 in total proceeds. Upon buying the shares at $1.87, the Director now owns 5,400 shares.
Before that, Pieper Steven bought 28,000 shares. Xeris Biopharma Holdings Inc shares valued at $54,600 were divested by the insider at a price of $1.95 per share. As a result of the transaction, Pieper Steven now holds 1,176,912 shares, worth roughly $2.48 million.
Craig Hallum initiated its Xeris Biopharma Holdings Inc [XERS] rating to a Buy in a research note published on August 28, 2023; the price target was $4.50. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late October with a ‘”a Buy”‘ rating. Craig Hallum began covering XERS with “Buy” recommendation on April 28, 2022. SVB Leerink started covering the stock on November 17, 2021. It rated XERS as “an Outperform”.
Price Performance Review of XERS
On Monday, Xeris Biopharma Holdings Inc [NASDAQ:XERS] saw its stock jump 0.48% to $2.11. Over the last five days, the stock has lost -0.94%. Xeris Biopharma Holdings Inc shares have fallen nearly -10.21% since the year began. Nevertheless, the stocks have risen 64.84% over the past one year. While a 52-week high of $3.26 was reached on 02/15/24, a 52-week low of $1.25 was recorded on 03/25/24. SMA at 50 days reached $2.63, while 200 days put it at $2.28. A total of 1.39 million shares were traded, compared to the trading of 1.76 million shares in the previous session.
Levels Of Support And Resistance For XERS Stock
The 24-hour chart illustrates a support level at 2.05, which if violated will result in even more drops to 1.99. On the upside, there is a resistance level at 2.19. A further resistance level may holdings at 2.27. The Relative Strength Index (RSI) on the 14-day chart is 33.47, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.11, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.88%. Stochastics %K at 2.84% indicates the stock is a buying.
How much short interest is there in Xeris Biopharma Holdings Inc?
A steep rise in short interest was recorded in Xeris Biopharma Holdings Inc stocks on Feb 29, 2024, growing by 0.24 million shares to a total of 9.64 million shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 9.4 million shares. There was a rise of 2.49%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 7.01% of the overall stock float, the days-to-cover ratio (short ratio) rose to 5.05.
The most recent change occurred on October 29, 2021 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $4 price target.
